---
document_datetime: 2026-01-23 17:40:20
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/ronapreve-epar-all-authorised-presentations_en.pdf
document_name: ronapreve-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.0528135
conversion_datetime: 2026-01-26 20:21:40.590237
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.70.0
  docling-core: 2.60.2
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength              | Pharmaceutical Form             | Route of Administration           | Immediate Packaging   | Content (concentration)                            | Pack size                                |
|------------------|-------------------|-----------------------|---------------------------------|-----------------------------------|-----------------------|----------------------------------------------------|------------------------------------------|
| EU/1/21/1601/001 | Ronapreve         | 300 mg / 300 mg       | Solution for injection/infusion | Intravenous use, Subcutaneous use | vial (glass)          | 2.5 ml (120 mg/ml) + 2.5 ml (120 mg/ml) authorised | 1 single dose vial + 1 single dose       |
| EU/1/21/1601/002 | Ronapreve         | 120 mg/ml / 120 mg/ml | Solution for injection/infusion | Intravenous use, Subcutaneous use | vial (glass)          | 11.1 ml + 11.1 ml                                  | vial 1 multidose vial + 1 multidose vial |

<!-- image -->